Dr. John Cush RheumNow
1 year 7 months ago
UKs University of Birmingham researchers have just been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis. https://t.co/or9amYqljz https://t.co/EvDhVfqOig
Dr. John Cush RheumNow
1 year 7 months ago
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/VH2ahP1XUy
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
Dr. John Cush RheumNow
1 year 7 months ago
Sedentary Behavior Increases the Risk of Gout
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia.
https://t.co/LDhK3iDnrS https://t.co/z6I6tRw9Fr
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.
Dr. John Cush RheumNow
1 year 7 months ago
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/IibXiitVY8 https://t.co/XHBQcdcMAE
Dr. John Cush RheumNow
1 year 7 months ago
Rheumatologist Survey: Active Lupus on pred + DMARD w/ (more than skin/Joint) organ & serologic activity- whats your preferred "add-on" drug?
Dr. John Cush RheumNow
1 year 7 months ago
Italian study of 458 #RA pts shows 16% (71)meeting the EULAR criteria for difficult 2 Rx RA ( D2T-RA); unrelated to age, gender, seropositivity. BUT D2T-RA was assoc w/ erosions (24% vs 11%), obesity (33% vs 19%) & FM (25% vs 10%) https://t.co/w5mliNkfBT https://t.co/m65jk62wmh
Dr. John Cush RheumNow
1 year 7 months ago
Retrospectively review of 165 #EGPA pts, GI manifestations were assoc w/ Eosinophils > 19.5%, weight loss, & myalgia; & included abdominal pain (78%), diarrhea (40%), N/V (33%); GI hemorrhage (27%), ulcers (17%), obstruction (10%), & pancreatitis (6%) https://t.co/EzsGcFs2l2 https://t.co/mQrgjTG6NV
Dr. John Cush RheumNow
1 year 7 months ago
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/AEJmW95vud https://t.co/3NnKjHQJtv
Dr. John Cush RheumNow
1 year 7 months ago
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/RxI1zlZ9YR https://t.co/vhsLi6HQAS
Dr. John Cush RheumNow
1 year 7 months ago
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/ug2ZzzSrGi https://t.co/O6r1e8ioO0
Dr. John Cush RheumNow
1 year 7 months ago
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus
https://t.co/aNk5pgBpiJ https://t.co/C427ayULng
Dr. John Cush RheumNow
1 year 7 months ago
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency
https://t.co/Fkn26crcNX https://t.co/LJVa0TApid
